Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial Results on Wednesday, April 22, 2020
22 avr. 2020 13h38 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, April 22, 2020 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company...
Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts
11 mars 2020 21h24 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross...
Interpace Diagnostics Announces Contract with BCBS of Massachusetts
10 mars 2020 06h55 HE
|
Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced...
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
02 mars 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s...
Interpace Announces Extension of LabCorp Agreement
24 févr. 2020 06h55 HE
|
Interpace Biosciences, Inc.
ThyGeNEXT and ThyraMIR Collaboration Extended for Another Two Years PARSIPPANY, NJ, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that its...
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
11 févr. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement...
Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership
30 janv. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Ron Rocca, CEO of Exagen, appointed to BoardJames Early, CFO announces retirement; Fred Knechtel, formerly CFO of GENEWIZ, appointed as CFOJeff Salzman, formerly of CareDX, appointed VP of Managed...
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
13 janv. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany,...
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
06 janv. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
17 déc. 2019 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...